Bristol-Myers Squibb Stock News

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH--Bristol Myers Squibb Data at ASH 2025 Showcases Potential of Hematology Pipeline and Builds Momentum for Next Generation Portfolio.

Drug companies face fairly normal industry dynamics that can leave them unloved on Wall Street over short periods of time. Pfizer is facing a patent cliff and is making a big move to revamp its drug pipeline.

Bristol Myers Squibb and Johnson & Johnson have had a tough past few years due to several factors. Both companies are looking to right the ship thanks to new product launches.

Bristol Myers has struggled to generate growth in recent years. Its high debt load has come down but remains a burden for the business.

Eight of the top fifteen Barron's Better Bets (BBB) 'Safer' dividend stocks, including Conagra, Altria, and Verizon, are currently attractively priced for income investors. Analyst forecasts project net gains of 18.44% to 29.95% for the top ten BBB Dogs by November 2026, with an average estimated gain of 22.01%. Stocks are considered 'dogs' when their reliable dividends and lower prices result ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in Citi's 2025 Global Healthcare Conference.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--BMS Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma.

Bayer issued a "surprisingly positive" report for its blood thinner over the weekend, prodding Bristol Myers Squibb stock higher on Monday.